argenex SE $ARGX Shares Bought by M&T Bank Corp

M&T Bank Corp grew its holdings in shares of argenex SE (NASDAQ:ARGX) by 34.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,980 shares of the company’s stock after purchasing an additional 1,286 shares during the period. M&T Bank Corp’s holdings in argenex were worth $4,188,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ARGX. AQR Capital Management LLC increased its position in argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares during the period. NewEdge Advisors LLC increased its position in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares during the period. Focus Partners Wealth increased its position in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares during the period. Geneos Wealth Management Inc. increased its position in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its position in argenex by 60.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $807.55 on Thursday. The business’s 50 day simple moving average is $756.94 and its 200-day simple moving average is $817.94. The firm has a market capitalization of $50.22 billion, a price-to-earnings ratio of 41.37, a price-to-earnings-growth ratio of 1.31 and a beta of 0.46. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62.

argenex (NASDAQ:ARGX) last posted its earnings results on Saturday, February 14th. The company reported $8.02 earnings per share (EPS) for the quarter. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, equities analysts anticipate that argenex SE will post 24.63 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on ARGX shares. Citizens Jmp boosted their target price on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Wedbush reissued an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research note on Monday, March 9th. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Royal Bank Of Canada decreased their price target on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Finally, Guggenheim decreased their price target on argenex from $1,160.00 to $1,120.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,016.22.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.